Servier To Refresh Neuroscience Space With New RNA-Oriented Precision Medicine Focus

As Immuno-Inflammation Pipeline Advances

The French firm’s stagnant neuroscience franchise will be revamped through a new, strategic focus on RNA-based precision medicines for neurodegenerative diseases including both small- and large-molecule drugs, the company tells Scrip.  

Yellow refresh symbol arrows on orange background
Servier Is Entering A New Era Of Neuroscience R&D • Source: Shutterstock

Les Laboratoires Servier is on a mission to add some spark to its neuroscience pipeline by developing RNA-targeting drugs for neurodegenerative conditions as it tries to follow in the footsteps of the likes of Biogen, Inc.’s Spinraza. Elsewhere, the company believes its immuno-inflammation pipeline could yield a new monoclonal antibody product for Sjörgen’s syndrome.

The French firm has a track record of developing and marketing novel neuroscience drugs including in the psychiatry space. Back...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By 

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention Data

 
• By 

Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By 

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

More from Scrip

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By 

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.